2015 San Antonio Breast Cancer Symposium: Arimidex, Tamoxifen, and Recurrence Risk After DCIS

episode

Breastcancer.org Podcast not yet transcribed

▲ 0

Transcript

This episode hasn't been transcribed yet Upvotes decide what gets transcribed next — 0 so far. Sign in to upvote

Related

recent transcribed audio

Maris Kreizman reads "To Save Free Enterprise, Books Must Die" 6 min · 23 Sep 2026 · In Your Spare Time: From the Blog of Ursula K. Le Guin

7AM ET 09/23/2026 Newscast 3 min · 23 Sep 2026 · Fox News Hourly Update

BravoAndy and Bronwyn’s Fanny (Headlines) 1h 0m · 23 Sep 2026 · Two Ts In A Pod with Teddi Mellencamp and Tamra Judge

MIT Dethrones Princeton as America’s Top School & The Viral Debate Over Bringing Iced Coffee to Job Interviews 30 min · 23 Sep 2026 · Morning Brew Daily

US diesel dilemma 6 min · 23 Sep 2026 · Wall Street Breakfast

The Great Autumn International Break of 2026™ 50 min · 23 Sep 2026 · Football Ramble

Report any issue

Source

Recorded19 Oct 2016

Publisherfeeds.megaphone.fm ↗

Handlerec:11088384

Show notes

In this podcast, Marisa Weiss, M.D., Breastcancer.org’s chief medical officer, explains a study that looked at the effectiveness of Arimidex and tamoxifen for reducing risk after DCIS surgery and radiation, as well as the side effects of each medicine. The study was presented at the 2015 San Antonio Breast Cancer Symposium, December 8-12. Listen to the podcast to hear Dr. Weiss explain: what DCIS is why postmenopausal women should be reassured no matter which of these medicines they’re taking the side effects of each medicine

Ask this episode

“What did the council decide on item 42?” — answered with the speaker and the moment.

Sign in